A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
← catalyst calendarNCT06212999 · readout in 129 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
617actual
Sites
165
Countries
Australia, Austria, Belgium +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-30 | actual | When the study began enrolling |
| Primary completion | 2026-12-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-26 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa (HS)
Intervention
- Drug: Povorcitinib — also filed as INCB054707
Primary outcome
what the primary-completion date above is the date OFProportion of participants with Treatment-Emergent Adverse Events (TEAEs)
measured up to approximately 56 weeks
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed